|Expense Ratio (net)||1.42%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||Average|
|Beta (5Y Monthly)||0.33|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Feb 01, 2012|
CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy," or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced that it has started the trial production of its special 26650 lithium battery (the "Special 26650 Battery"). Different from our regular 26650 batteries that the company is currently manufacturing and selling, the Special 26650 Battery is a self-developed battery model specifically designed for application in ultra-low temperature environments. The Special 26650 Battery has delivered satisfactory test performance results to date, while the trial's production yield rate has also been very close to our required level for mass production. The Company believes that it will be capable of achieving mass delivery of its Special 26650 Battery by the second half of 2021.
In this article, we take a look at some of the expected highlights of the next energy revolution. You can skip our detailed discussion of the energy market and go directly to 5 emerging energy technologies you can invest in today. Innovation in energy has changed the way companies offer sustainable products and services. These […]
CBAK Energy Technology, Inc. ("CBAK Energy," or the "Company," NASDAQ: CBAT), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced that it closed a registered direct placement of approximately $70 million of its common stock, priced at the market under applicable Nasdaq rules with a price of $7.83 per share, and the concurrent private placement on February 10, 2021, as previously announced on February 8, 2021. The Company issued a total of 8,939,976 shares of common stock to certain institutional investors. The Company also issued Series A-1 Warrants to the investors to purchase a total of 4,469,988 shares of common stock and Series A-2 Warrants to purchase up to 2,234,992 shares of common stock, both of which were issued at an exercise price of $7.67 per share. Series A-1 Warrants and Series A-2 Warrants are exercisable for 42 months and 45 months, respectively, from the issue date. In addition, the Company issued Series B Warrants to the same investors to purchase a total of 4,469,988 shares of common stock at an exercise price of $7.83 per share, which are exercisable for 90 days from the issue date.